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Abstract
Background: RC-101, a cationic peptide retrocyclin analog, has in vitro activity against HIV-1. Peptide drugs are
commonly prone to conformational changes, oxidation and hydrolysis when exposed to excipients in a
formulation or biological fluids in the body, this can affect product efficacy. We aimed to investigate RC-101
stability under several conditions including the presence of human vaginal fluids (HVF), enabling the efficient
design of a safe and effective microbicide product. Stability studies (temperature, pH, and oxidation) were
performed by HPLC, Circular Dichroism, and Mass Spectrometry (LC-MS/MS). Additionally, the effect of HVF on
formulated RC-101 was evaluated with fluids collected from healthy volunteers, or from subjects with bacterial
vaginosis (BV). RC-101 was monitored by LC-MS/MS for up to 72 h.
Results: RC-101 was stable at pH 3, 4, and 7, at 25 and 37°C. High concentrations of hydrogen peroxide resulted in
less than 10% RC-101 reduction over 24 h. RC-101 was detected 48 h after incubation with normal HVF; however,
not following incubation with HVF from BV subjects.
Conclusions: Our results emphasize the importance of preformulation evaluations and highlight the impact of HVF
on microbicide product stability and efficacy. RC-101 was stable in normal HVF for at least 48 h, indicating that it is
a promising candidate for microbicide product development. However, RC-101 stability appears compromised in
individuals with BV, requiring more advanced formulation strategies for stabilization in this environment.
Background
Microbicides are being investigated as a potential alter-
native for the prevention of HIV. Microbicide products
would be applied vaginally or in the rectum before
intercourse to prevent transmission and acquisition of
sexually transmitted infections (STIs), mainly human
immunodeficiency virus (HIV) [1,2]. Several microbicide
candidates with different mechanisms of action are
being investigated [3]. The interaction of microbicide
drug candidates with human vaginal fluids can result in
chemical modification of the drug by oxidation, hydroly-
sis, or proteolysis, thereby decreasing its potential for
biological activity.
Defensins are cysteine-rich, cationic antimicrobial pep-
tides expressed by the leucocytes and epithelial cells of
mammals. Defensins have been shown to protect cells
from in vitro infection by human immunodeficiency
virus (HIV-1). Retrocyclins (θ-Defensin) are the evolu-
tionary descendants of a-defensin genes. Retrocyclins
are circular 18-residue, tetracyclic peptides with three
cysteine disulfide bonds. RC-101 (GICRCICGKGICR-
CICGR), a cationic retrocyclin analog synthesized by
solid phase peptide synthesis, has shown activity against
X4 and R5 strains of HIV-1 in vitro [4]. The mechanism
occurs by preventing six-helix bundle formation of gp41
(a 41,000 MW glycoprotein), conferring a strong
mechanism of protection against HIV-1 [5]. As a result,
RC-101 has been identified as a potential microbicide
candidate to prevent mucosal transmission of HIV-1 [5].
Biopharmaceuticals (proteins and peptides) have
demonstrated advantages over small molecule
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the target, offer less adverse effects, and provide a more
effective treatment. However, it is challenging to formu-
late a protein or peptide into a microbicide product.
The product must overcome in vivo barriers that will
affect efficacy of the product. Changes in efficacy can be
related to: 1) protein modification, mostly due to con-
formational changes; 2) chemical degradation in the
drug delivery vehicle; 3) proteolytic inactivation in the
vaginal lumen, and/or 4) low penetration of the drug
into the mucosal tissue [6]. It is crucial to understand,
through a complete pre-formulation study, how condi-
tions of temperature, pH, and oxidative effects will affect
the protein or peptide. A preformulation study will
expedite formulation of a successful microbicide
product.
Vaginal fluid covers the vaginal epithelium and pro-
tects against entry of pathogens into deeper tissues. Cer-
vical mucus has similar functions and additionally
facilitates sperm penetration by changing its viscoelastic
properties during ovulation. Properties of the mucus
layer can either facilitate or impede the efficacy of a
drug product. When a vaginal microbicide product is
applied, its presence should not disrupt the natural pro-
tective mechanisms associated with the mucus layer. In
some cases, vaginal fluids may be disadvantageous. The
presence of physiological fluids may alter the character-
istics of a vaginal product, which can reduce the overall
efficacy of the drug substance, increase leakage, and
decrease drug residence time at the target tissue [7].
More importantly, enzymatic activity and the presence
of hydrogen peroxide produced by Lactobacillus greatly
affect the stability of protein and peptide microbicide
agents. This enzymatic barrier in vaginal fluid has been
identified as a major barrier to the delivery and absorp-
tion of microbicides and other drugs [8].
The purpose of this study was to determine the stabi-
lity of RC-101 in several conditions including the pre-
sence of human vaginal fluids, to describe the
degradation pathways, and to investigate the protective
effects of excipients against oxidation. In this study, sev-
eral pre-formulation evaluations were performed for
RC-101 to provide information needed to develop vagi-
nal formulations of RC-101 for use as a topical microbi-
cide product. This characterization included an
evaluation of the stability of RC-101 in the presence of
vaginal fluids, selected conditions of temperature, pH,
and the presence of hydrogen peroxide.
Methods
Materials
Retrocyclin-1 (RC-101) was synthesized by the Peptide
Synthesis Facility at the University of Pittsburgh (Pitts-
burgh, PA). As part of quality control of the material,
mass spectrometry using a Quattro II triple quadrupole
mass spectrometer electrospray ionization (Fisons Inc.,
Valencia, CA) and AU-PAGE were conducted to con-
firm identity and the molecular weight of the com-
pound, and in vitro activity using TZM cells was
conducted to confirm bioactivity of RC-101 against
HIV-1. Acetonitrile (HPLC grade), trifluoracetic acid
(TFA), sodium phosphate dibasic, phosphoric acid
(85%), sodium acetate, and glacial acetic acid were
obtained from Fisher Scientific (Fair Lawn, NJ). Urea
was purchased from Spectrum Laboratory Products Inc.
(Gardena, CA). Polyvinyl alcohol (PVA) was obtained
from Kuraray America Inc. (New York, NY). Glycerin
was obtained from Dow Chemical Company (Midland,
MI). All other materials were obtained from Sigma (St.
Louis, MO). De-ionized water was prepared from
house-distilled water with a Milli Q (Millipore, Milford,
MA) water system operating at 18.2 MΩcm.
Pre-formulation studies
For all pre-formulation studies described below, tripli-
cate solutions of RC-101 (500 μg/mL) were prepared in
either water or aqueous buffer solution. Thermal degra-
dation studies were conducted at 25, 37, and 65°C for a
minimum period of 1 week. The effect of pH on the sta-
bility of RC-101 was evaluated over the pH range from 3
to 12 using 10 mM phosphate buffer solutions, at low
(50 mmol/kg) and high (500 mmol/kg) ionic strength.
Oxidation of RC-101 was evaluated by exposing a solu-
tion of RC-101 to hydrogen peroxide (H2O2) at concen-
trations of 3.0, 0.08, and 0.002% (v/v). The high H2O2
concentration (3.0%) was selected as a forced degrada-
tion concentration. More biologically relevant concen-
trations (0.002% and 0.08% H2O2) were selected based
on reported studies which determined the amount of
hydrogen peroxide produced by Lactobacillus present in
the normal vaginal flora, and estimated calculations
based on concentrations of Lactobacillus present [9,10].
Protection against oxidation was investigated by the
addition of antioxidants commonly used in pharmaceu-
tical products. The antioxidants used in this study were:
methionine (95.2 μg/mL or 250 μg/mL), cysteine (95.2
μg/mL), glutathione (90.9 μg/mL), vitamin E TPGS (90.9
μg/mL), ascorbic acid (1.0 mg/mL), sodium ascorbate
(1.0 mg/mL), and EDTA (1.0 μg/mL).
RC-101 concentration after exposure to preformula-
tion conditions was analyzed by HPLC as previously
described [11]. Briefly, the HPLC system (Waters Cor-
poration, Milford, MA) was equipped with an autoinjec-
tor model 717, a quaternary pump model 600, and an
ultraviolet (UV) detector model 2487 set up at 215 nm.
Separation of RC-101 from degradant products was
achieved using a Phenomenex Jupiter 5 μC5 300 Å (4.6
× 250 mm) column (Phenomenex, Torrance, CA)
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tridge (Phenomenex). The gradient consisted of mobile
phase A (0.1% TFA in water (v/v)), and mobile phase B
(0.07% TFA in acetonitrile (v/v)) pumped at a flow rate
of 1.0 mL/min. Forced degraded samples (oxidation,
temperature, and basic and acidic hydrolysis) were used
to establish that the method could separate the degra-
dants from the main peak.
Changes in the secondary structure of the protein
were monitored by Circular dichroism (CD) on an
AVIV Circular Dichroism spectrophotometer model 202
(AVIV Biomedical, Lakewood, NJ) equipped with a 0.1
cm path length quartz cell. RC-101 stability was also
monitored by using a matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) mass spectro-
metric (MS) on a Voyager DE-PRO mass spectrometer
(Applied Biosystems, Foster City, CA). Potential for
aggregation was evaluated by UV-spectroscopy using a
NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies Inc, Wilmington, DE).
Human vaginal fluids collection protocol
Human vaginal fluid (HVF) was collected from 17
healthy premenopausal women according to protocol
IRB number REN11050038/PRO07050142, approved by
the Institutional Review Board under 45 CFR 46.110.(9).
Inclusion criteria included ages between 18 and 45 years
and agreeing to be abstinent from sexual activity for 48
hours prior to fluid collection. Women who were found
to be pregnant, or to have used vaginal products or to
have sexual intercourse in the 48 hours prior to collec-
tion were excluded. After signing informed consent and
confirming eligibility, subjects completed a questionnaire
and were then instructed on the use of the Instead Soft-
cup
® (Instead Inc., La Jolla, CA) [12]. Instead Softcup
®
is a FDA approved device to hold menstrual fluid during
the menstrual period in replacement of a tampon or
pad. Subjects inserted the cup and waited for 30 min.
After this time period, the physician removed the cup,
and placed it into a 50 mL conical centrifuge tube. Vagi-
nal fluid collected from healthy volunteer women was
stored at 4°C until used, and it was used within 4 h
after collection. Usual volumes collected using the Soft-
cup ranged from 0.1 to 0.8 mL depending on the
subject.
After removing the Instead Softcup
®,as p e c u l u m
examination was performed. Swab specimens of the
endocervix were obtained using the Mini-tip Culturette
TN collection system (Becton Dickinson, Sparks, MD)
according to the manufacturer’s guidelines. C. tracho-
matis and N. gonorrhoeae were detected with an ampli-
fied DNA assay based on the simultaneous amplification
and detection of target DNA amplification primers and
a fluorescent label detector probe [13]. Bacterial
vaginosis was detected by Gram stain and assessed by
the Nugent score, where score results between 0 and 3
indicate a normal flora, between 4 and 6 indicates an
intermediate state, and between 7 and 10 indicates bac-
terial vaginosis [14]. Subjects were notified of the test
results by telephone within two weeks of collection and
directed to the Allegheny County Public Health Depart-
ment (Pittsburgh, PA) for treatment and additional test-
ing, if needed.
Preparation of RC-101 solution and film formulation
RC-101 100 μg/mL solutions were prepared by dissol-
ving RC-101 in Milli Q water. RC-101 and placebo films
were prepared by precasting a polymeric film solution
into an 8-well-plate. The polymeric film solution was
prepared as previously described [15] by adding Milli Q
water, PVA, and hydroxypropyl methyl cellulose
(HPMC). The solution was then heated at 95°C for 20
minutes for complete dissolution of the polymers. After
cooling, glycerin and RC-101 were added. Film solution
(2.4 g) containing RC-101 was poured into each well of
the 8-well plate. The plate was placed into a vacuum
oven at 30 ± 2°C for 20 ± 4 h. All dried films were
r e m o v e df r o mt h ep l a t e sa n ds t o r e da tr o o mt e m p e r a -
ture in PET/Aluminum foil pouches (Amcor Flexibles
Healthcare Inc, Mundelein, IL) until further analysis.
Placebo films were prepared in the same way without
the addition of RC-101. Each RC-101 film contained
100 μg of RC-101. For analytical purposes, films were
dissolved in 1 mL of Milli Q water before addition to
HVF.
Preparation of RC-101 + HVF sample
The HVF from the Instead Softcup
® was removed by
centrifugation of the conical tube for 10 min at 5,000
rpm. This first centrifugation allowed for an efficient
removal of the HVF from the Instead Softcup
®.H V F
was then removed from the cup and the pH of each
HVF sample was measured with Fisher Alkacid pH filter
strips (Fisher Scientific). All samples collected on a spe-
cific day were pooled to be used for the research studies.
If the pH of the individual samples was higher than 5,
t h es a m p l ew a sn o ti n c l u d e di nt h ep o o lb u ti tw a s
stored at -80°C for separate analysis. If the sample con-
tained blood, it was immediately discarded. Samples
were prepared as described in Table 1. All samples (RC-
101 solution, RC-101 film or placebo film) were com-
bined with vehicle (HVF or water) in a ratio of 1:1.
Because of its high viscosity, HVF was measured by
weight and not by volume. All solutions were prepared
fresh and incubated with HVF (or water) at 37°C for
specific periods of time (0, 2, 6, 12, 24, 48, and 72 h),
unless specified otherwise. At each time point, the sam-
ples were centrifuged at 10,000 rpm for 10 min to
Sassi et al. AIDS Research and Therapy 2011, 8:27
http://www.aidsrestherapy.com/content/8/1/27
Page 3 of 11separate the supernatant from the epithelial cells as
described in the cell processing section. Both parts
(supernatant and cells) were stored at -80 ± C until ana-
lyzed by LC-MS/MS. To evaluate the influence of freez-
ing the fluid prior to the analysis, the last pool of HVF
was divided into two samples: one used fresh (at the
time of collection), and the other one stored at -80°C
for a 3-month period. After that time period, HVF was
thawed and processed for blank and RC-101 solution
only, as described in Table 1. HVF samples collected
with a high pH value indicative of BV were stored at
-80°C as previously mentioned. After confirmation of
BV on those fluid samples by Gram stain score, the
fluid samples (HVF BV
+) were thawed, pooled, and pro-
cessed as described in Table 1.
Sample processing for analysis
At each time point, the sample was removed from the
incubation chamber and centrifuged for 10 min at
10,000 rpm, at 4 ± C to separate the supernatant from
cell pellet. Supernatant (100 μL) was added to microcen-
trifuge filters Ultracel YM-10 Microcon MWCO 10,000
(Millipore Corporation, Bedford, MA), which were pre-
washed with Milli Q water to eliminate any trace of pro-
pylene glycol from the filters. Samples were centrifuged
twice for 15 min at 8,500 rpm, at 4 ± C. The filtrate
was collected and frozen at -80 ± C until further analy-
sis. A solution of 3 M urea was added to the cell pellet
(1:1 w/w) obtained from the first centrifugation, to lyse
the cells. This mixture was vortexed three times for 30
sec, and then centrifuged for 10 min at 10,000 rpm, at 4
± C. The supernatant obtained from the cell lysate was
then added to microcentrifuge filters Ultracel YM-10
Microcon MWCO 10,000 pre-washed with Milli Q
water. Samples were centrifuged twice for 15 min at
8,500 rpm, at 4 ± C. The filtrate was collected and fro-
zen at -80 ± C until analysis. The peptide RC-101 has
been shown to be stable in 3 M urea for at least 24 h.
Samples were thawed and added to PepCleanTM C-18
spin columns (Pierce Biotechnology Inc., Rockford, IL)
for desalting, after column conditioning with acetoni-
trile:water (50:50) and equilibration with 0.1% trifluoroa-
cetic acid. The column was washed three times with
0.1% trifluoroacetic acid, and RC-101 was eluted with
acetonitrile:water (60:40) in 0.1% trifluoroacetic acid.
Samples were dried in a speed vacuum CentriVap con-
centrator (LabConco Corp., Kansas City, MO) and
resuspended with 200 μL of Milli Q water for LC-MS/
MS analysis. Each sample described in Table 1 origi-
nated two sets of samples: one labeled as supernatant
and the second one labeled as cells.
Nanoflow Liquid Chromatography Selected Reaction
Monitoring (SRM) Mass Spectrometry
Integrated electrospray ionization (ESI)-capillary
reversed-phase columns (75 μm inner diameter × 360
μm outer diameter × 100 mm length) packed with 5 μm
300 Å pore size Jupiter C18 reversed-phase stationary
phase (Phenomenex) were prepared, as previously
described [16]. Solvent flow was supplied by a nanoflow
Table 1 Summary of RC-101, in solution and formulated, samples combined with HVF
Sample
Code
Sample
Description
HVF RC-101
(100 μg/mL)
SOLUTION
Water RC-101
100 μg/
FILM*
Placebo
FILM*
A Blank HVF 100 mg ——— 100 μL ——— ———
B RC-101 solution
combined with HVF
100 mg 100 μL ——— ——— ———
C RC-101 solution control ——— 100 μL 100 μL ——— ———
D RC-101 film
combined with HVF
100 mg ——— ——— 100 mg ———
E RC-101 film control ——— ——— 100 μL 100 mg ———
F Placebo film
combined with HVF
Not performed ——— ——— ——— ———
G Placebo film control ——— ——— 100 μL ——— 100 mg
AF Blank HVF frozen 100 mg ——— 100 μL ——— ———
BF RC-101 solution
with frozen HVF
100 mg 100 μL ——— ——— ———
ABV+ Blank HVF BV
+ 100 mg ——— 100 μL ——— ———
B BV+ RC-101 solution
with HVF BV
+
100 mg 100 μL ——— ——— ———
Amounts correspond to one time point.
*RC-101 film and placebo film were initially dissolved in 1 mL of water prior to addition to HVF. Amounts in the films columns correspond to the solution of the
film in 1 mL of water.
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n y v a l e ,C A ) .E a c hs a m p l e( 3μL) was loaded onto the
column through a 5 μL loop at a flow rate of 0.5 μL/
min in 98:2 mobile phase A (0.1% formic acid in water,
v/v) and mobile phase B (0.1% formic acid in acetoni-
trile, v/v) for 30 min. The step-wise linear gradient was
delivered at 250 nL/min as follows: 2 to 40% mobile
phase B over 40 min, followed by 40 to 98% mobile
phase B over 30 min. High voltage contact for ESI was
provided through a metal union connecting the micro-
capillary column to the pump. The RC-101 peptide
abundance was measured by SRM using a triple quadru-
pole MS (TSQ Quantum Ultra, Thermo Fisher Scientific
Inc., San Jose, CA). While operating in SRM mode, Q1
and Q3 resolutions were set to 0.7 atomic mass unit
(amu), and the collision induced dissociation (CID) gas
pressure was 1.5 mTorr with a collision energy (CE) of
18 volts. Each SRM scan width was set to 0.002 m/z
units and the scan rate was 0.020 sec. RC-101 peptide
abundance was measured by selected reaction monitor-
ing (SRM). Initially, confirmation of the peptide detec-
tion was obtained on a high resolution Orbitrap mass
spectrometer (Thermo Scientific). The initial base peak
chromatogram with a representative mass spectrum of
the [M + 4H]
4+ RC-101 molecular ion was obtained
(data not shown).
After the incubation period of RC-101 combined with
HVF, each sample (described in Table 1) was removed
from the incubation chamber and processed for LC-MS/
MS analysis as described above. For each condition ana-
lyzed, supernatant and cells, the LC-MS/MS chromato-
gram was obtained. Data were analyzed by construction
of mass chromatograms for each SRM transition sepa-
rately, and peak areas were manually tabulated
Statistical analysis
HPLC data obtained from the preformulation studies
were expressed as the average percentage of the peak
area from time 0 ± standard deviation, n = 3. Results
were analyzed by one-way analysis of variance
(ANOVA) with multiple comparisons of individual time
points by using post hoc Bonferroni correction to detect
significant differences under different conditions. P-
values ≤ 0.05 were considered to be statistically signifi-
cant, unless specified otherwise.
Results and Discussion
Recently, several biopharmaceuticals (proteins and pep-
tides) have been investigated as potential microbicides
for prevention of HIV [6,17-19]. However, formulation
and delivery of biopharmaceuticals can be difficult due
to degradation and targeting challenges. A successful
formulation will protect the peptide against degradation
during the manufacturing process, during the shelf-life
of the product, and after the protein enters the biologi-
cal system [20,21]. According to the Alliance for Micro-
bicide Development [2], several needs in microbicide
formulation are considered to have a high priority, this
includes preformulation evaluation. The current study
addressed this issue by characterizing the stability of
RC-101 and thereby informing the formulation develop-
ment and, improving the efficacy of the product.
RC-101 (MW = 1890.42) (GICRCICGKGICRCICGR)
is a circular cationic 18-residue peptide, tetracyclic pep-
tide with three cysteine disulfides bonds [22]. Preformu-
lation studies showed that no statistically significance
difference was observed for RC-101 stored at 25 and 37
± C for a period of 13 days (p > 0.5), post hoc Bonfer-
roni correction for multiple comparisons applied. Sam-
ples stored at 65 ± C showed a significant decrease in
the amount of RC-101 at 168 h (p < 0.04) compared to
R C - 1 0 1i n c u b a t e df o rt h es a m et i m ep e r i o da t2 5±C
(Figure 1A). MALDI-TOF MS was used to confirm the
m/z of RC-101 (Figure 1B). Stability at 37 ± C suggests
that the peptide will be stable at body temperature for a
prolonged period of time. Protein stability at high tem-
peratures should be considered not only to understand
how the drug will be affected in the body, but also how
the compound will behave during the manufacturing
process when high temperature may be required for
processing. In addition, this information would be useful
to predict shelf-life. The data showing that RC-101 is
susceptible to degradation at 65 ± C indicates that the
manufacturing process of a RC-101 microbicide product
should avoid prolonged exposure of the drug to high
temperatures. However, chemical stability of RC-101
under temperature conditions is superior to several
other proteins studied that showed fast thermal degrada-
tion at temperatures higher than 40°C [23,24].
The peptide RC-101 was shown to be stable in phos-
phate buffer solutions of pH 3, 4 and 7 using HPLC
assay. Concentration of RC-101 by HPLC over time at
different pH is shown in Figure 2A. Post hoc Bonferroni
analysis for multiple comparisons was applied and no
statistically significant decrease was observed over a per-
iod of 10 days for the samples at pH 3, 4, and 7 (p >
0.83). A significant decrease was observed at pH 12 in
t h ef i r s t2h .C Dw a sc o n d u c t e do nb u f f e rs o l u t i o n so f
500 μg/mL RC-101 at pH 3, pH 7, and pH 12 (Figure
2B). Under all conditions, the protein showed a random
conformation, with a maximum absorbance at 230 nm
and a minimum absorbance at 200 nm for pH 3, 205
nm for pH 7, and 210 nm for pH 12. The peak shift in
the wavelength and the loss of absorbance for pH 7 and
pH 12 samples when compared to the pH 3 indicate a
change in folding of the protein. However, the change
observed at pH 7 did not affect bioactivity of RC-101
against HIV-1 (data not shown).
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strength buffers (pH 4 and 7) did not show any signifi-
cant differences in stability profiles, increasing the flex-
ibility for formulation development. UV scans of RC-
101 (500 μg/mL) in phosphate buffers pH 4, 7, and 12
were conducted (data not shown). Similar scans were
observed for RC-101 pH 4 and 7; however, an increase
in the absorbance at pH 12 samples was observed in the
range of 300 to 600 nm, indicating the presence of
aggregates. The stability of RC-101 in acidic pH is an
important finding as the drug will be exposed to the
acidic environment of the normal vagina with a pH (3.5
to 5.0). In addition, since the peptide is stable from pH
3 to 7, it expands the pH range for formulation of the
microbicide product. This will be important for when
the product is exposed to semen. The development of a
successful peptide microbicide product is primarily
dependent on the ability to prevent the oxidative effects
of H2O2, present in the vaginal lumen. The stability of
RC-101 was investigated under different levels of hydro-
gen peroxide. Forced degradation studies to evaluate
oxidative effects are commonly conducted by exposing
the molecule of interest to a solution of 3.0% H2O2 [25].
Results of RC-101 (500 μg/mL) exposed to 0.002, 0.08
and 3.0% hydrogen peroxide are shown in Figure 3A.
RC-101 quickly degraded in the presence of 3.0% H2O2
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slower in the presence of more biologically relevant con-
centrations (0.002% and 0.08% H2O2). Biologically rele-
vant levels were selected based on reported studies
which determined the amount of hydrogen peroxide
produced by Lactobacillus present in the normal vaginal
flora, and estimated calculations based on concentra-
tions of Lactobacillus present [9,10]. RC-101 amino acid
sequence contains six cysteines which are prone to oxi-
dation; however the cysteines are present in their oxi-
dized form, decreasing the likelihood of oxidative
degradation. The intramolecular disulfide bonds may
further oxidize resulting in sulfenic acid. The oxidation
of the cysteine residues is a metal-ion catalyzed oxida-
tion reaction. Most of the antioxidants used in this
study did not show a significant protective effect against
oxidation by the presence of hydrogen peroxide. Ethyle-
nediamine tetraacetic acid (EDTA) was the only antioxi-
dant investigated that showed protection of RC-101
against oxidation after exposure to H2O2 (Figure 3B).
EDTA is a widely used chelating agent, approved by the
Food and Drug Administration (FDA) as a preservative
for pharmaceutical products.
Further formulation development may include the
addition of EDTA. However, preliminary studies con-
ducted in our laboratory have shown that EDTA is toxic
to human ectocervical tissue and normal vaginal micro-
flora in concentrations of 1% or higher (data not
shown). Due to this fact, this preservative should be
further characterized regarding its potential for toxicity
in vivo.
Protection of RC-101 against oxidation may be neces-
sary during the shelf-life of the final formulation and
during the delivery in the vaginal lumen. The result
from the addition of EDTA to the RC-101 solution is
indicative of a method to protect RC-101 from oxidation
during shelf-life of the product. In a biological environ-
ment, when the microbicide product is administered
intra-vaginally, it will encounter the presence of vaginal
fluids and cervical mucus that will not only dilute the
microbicide agent, but also be a potential for degrada-
tion. The enzymatic activity present may initiate degra-
dation of the peptide, in addition to the normal vaginal
flora that produces hydrogen peroxide which will accel-
erate oxidation of RC-101. Our studies have shown that
R C - 1 0 1i ss u s c e p t i b l et oo x i d a t i o n ,b u ti nav e r ys l o w
kinetic of degradation. Depending on the time for bind-
ing of RC-101 to receptors and glycoproteins, oxidation
o fR C - 1 0 1a f t e r4 8hm a yb ea ni r r e l e v a n td e g r a d a t i o n
pathway and may not affect bioactivity. It is still
unknown how long the drug should be active in the
vaginal lumen, but it has been suggested that the virus
stays in the vaginal lumen for a period of 48 h [26,27].
If that is the case, short-term protection of RC-101 may
be sufficient to overcome oxidative degradation path-
ways in the vaginal lumen and guarantee biological
activity.
An important factor is to investigate the stability of
R C - 1 0 1i nt h ep r e s e n c eo fb i o l o g i c a lf l u i d s .I nt h i s
study, RC-101 was also investigated after combination
with fresh undiluted human vaginal collected from
healthy female volunteers.
Human vaginal fluid (HVF) was collected from a total
of 17 female premenopausal women. The fluid collected
represented individuals with a mean age of 31 ± 8 years.
Average pH for normal fluid samples collected was 4.5
± 0.6. None of the participants were using a vaginal ring
or Intra Uterine Device (IUD) as contraceptive. None of
the subjects tested positive for either C. trachomatis or
N. gonorrhoeae. Samples from volunteers were pooled
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Figure 3 Effect of hydrogen peroxide on RC-101. A) RC-101 under different concentrations of hydrogen peroxide over time analyzed by
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analyzed by HPLC.
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Page 7 of 11on the day of collection generating 3 pools (Pool 1, 2
and 3) for normal HVF, and one pool (BV pool) for
HVF positive for BV. All the data obtained from the
questionnaire was compiled for each pool and the most
relevant data is presented in Table 2.
Several factors such as menstrual status, oral contra-
ceptive use, and age will affect the amount and charac-
teristics of vaginal fluids [28-30]. The questionnaire
applied to all participant volunteers to characterize the
demographics of the population included but was not
limited to: day of the menstrual cycle, drinking status,
and smoking status. Due to the number of volunteers
used and the necessity to pool samples to obtain a sig-
nificant volume for the analysis, we were unable to
make any conclusions regarding the demographics infor-
mation collected and the stability of RC-101 in the
fluids.
This is the first study in the microbicide field to evalu-
ate a microbicide candidate using fresh HVF. After the
incubation of RC-101 with HVF, abundance of the pep-
tide was measure by LC-MS/MS. Representative LC-
MS/MS chromatograms at time 0 are shown in Figure 4
for Sample A supernatant (blank HVF), Sample B super-
natant (RC-101 solution + HVF) at 72 h, Sample C
supernatant (RC-101 solution control), and Sample D
(RC-101 film + HVF) at 48 h. Sample A (HVF control)
showed the presence of several peaks; however, no inter-
ference peaks were detected, indicating that the method
was suitable for detection of RC-101. For all other chro-
matograms, the m/z was confirmed for RC-101 detec-
tion. Since the LC-MS/MS method developed is not a
quantitative method, the amount of RC-101 was not
obtained. Overall, RC-101 was detected for 48 h in two
pools tested and up to 72 h in another pool tested. For-
mulation of RC-101 into the film still maintained the
stability of RC-101 over the same time period. Overall,
RC-101 was detected after exposure to HVF at least for
48 h, and no difference was observed for RC-101 in a
solution or a film formulation.
To verify if the freezing process would interfere with
the stability of RC-101 in the fluid, frozen HVF was
used for incubation with RC-101 solution (Sample BF).
I tw a se x p e c t e dt h a tR C - 1 0 1w o u l db ed e t e c t e da ta
higher concentration when using frozen HVF, due to
the suspected decrease in enzymatic activity of the fluid
upon freezing. Since the LC-MS/MS method is not
quantitative, it was not possible to determine this differ-
ence in concentration. No detectable differences were
observed in the peptide after incubation with frozen
fluid.
Stability of RC-101 over time was also investigated in
bacterial vaginosis (BV) fluido b t a i n e df r o mv o l u n t e e r s
(HVF BV
+). These samples were collected and stored at
-80°C, prior to incubation with RC-101. When RC-101
was combined with HVF BV
+ Pool (samples BBV
+), RC-
101 was undetectable in the LC-MS/MS analysis at any
time point studied, demonstrating that RC-101 was not
stable in those fluids. No RC-101 was detected at any
time point in the Sample BBV
+ in either supernatant or
cells. The results are summarized in Table 3.
If RC-101 can be detected in HVF for at least 48 h, it
is suggested that RC-101 will be available for binding to
gp120 during that time period, conferring protection
against HIV. The prolonged stability of RC-101 in HVF
indicates that this molecule is a promising candidate to
be delivered vaginally and can survive the enzymatic
activity present in normal vaginal fluid. However, further
studies in vivo are recommended to confirm the results
obtained. Another advantage of the stability of RC-101
for at least 48 h in HVF is the dose regimen selected for
the microbicide. The stability suggests that the final RC-
101 microbicide product could be applied once every
two days or once a day, without being coitally-depen-
dent. This would increase patient adherence to the pro-
duct, which may be more favorable to a successful
product. As a future study, the RC-101 detected after
incubation with HVF should be tested for bioactivity
against HIV.
The impact of HVF positive for bacterial vaginosis
(BV) has also been investigated. It has been shown that
RC-101 was completely unstable in fluid positive for BV
evidenced by the undetectable levels of RC-101 after
exposure to HVF positive for BV at all time points.
Some studies have evaluated the difference between nor-
mal HVF and HVF positive for BV, and a difference in
the enzymatic activity between a normal fluid and a BV
Table 2 Demographics of the subjects whose samples
were pooled, per sample pool
Characteristic Pool 1 Pool 2 Pool 3 BV Pool
Age
Mean ± SD 28.7 ± 6.7 30.6 ± 8.9 33.2 ± 7.8 35.2 ± 5.2
pH 4.1 ± 0.3 4.3 ± 0.3 4.1 ± 0.4 5.8 ± 0.6
BV score
Between 0 and 3 3 (75.0) 5 (71.4) 3 (50.0) 0
Between 4 and 6 1 (25.0) 2 (28.6) 1 (16.7) 1 (25.0)
Between 7 and 10 0 0 2 (33.3) 3 (75.0)
Last sexual intercourse
Between 2 and 5
days prior
1 (25.0) 1 (14.2) 2 (33.3) 2 (50.0)
6 or more days prior 3 (75.0) 3 (42.8) 3 (50.0) 2 (50.0)
Not sexually active 0 3 (42.8) 1 (16.7) 0
Currently using vaginal
products
Yes (more than 2
days prior)
0000
No 4 (100.0) 7 (100.0) 6 (100.0) 4 (100.0)
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Page 8 of 11positive fluid has been demonstrated [9,30-32]. BV is
characterized by a reduction in vaginal colonization by
Lactobacillus and an overgrowth of anaerobic gram-
negative bacteria. Intensive production of hydrolytic
enzymes in BV [31-33] may lead to a decreased mucosal
barrier in the vaginal and cervical mucosa. The higher
enzymatic activity found in BV might explain the
immediate degradation of RC-101 in the presence of
HVF positive for BV. In addition, electrostatic interac-
tions between cationic peptides and the anionic surface
of bacteria may occur [34], leading to possible adher-
ence of RC-101 to the BV bacteria which may explain
the decrease in the presence of RC-101. This finding is
extremely important for designing future studies for the
development of biopharmaceuticals and other molecules
as microbicides. Bacterial vaginosis is a highly prevalent
condition, affecting almost one third of women between
the ages of 14 and 49 years old in the United States,
according to the 2001 - 2004 National Health and
Nutrition Examination Survey [35]. Considering the
high prevalence of BV, further studies should investigate
the effects of HVF positive for BV on the stability of
microbicide drug candidates. Furthermore, more
advanced drug delivery strategies focused on protection
of RC-101 from BV positive fluids, such as encapsula-
tion of RC-101 in nanoparticles, may be needed prior to
consideration of application in this population of
women.
Another point to be considered is the rectal use of
microbicide. Although rectal delivery was not part of
the scope of our research, we understand that microbi-
cide formulation development should consider the stabi-
lity of the active microbicide ingredient in the presence
of rectal fluids.
Conclusions
This study has characterized the degradation pathways
of RC-101 under various conditions, which are essential
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Figure 4 Representative LC-MS/MS chromatograms for A) Sample A supernatant (blank HVF) at time 0, B) Sample B supernatant (RC-101
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Page 9 of 11for the development of an effective microbicide product.
It was shown that the microbicide drug candidate RC-
101 is stable over a wide range of pH, temperatures and
concentrations of hydrogen peroxide. RC-101 remained
present in human vaginal fluid (HVF) for at least 48 h
after incubation at 37°C, suggesting that RC-101 would
be stable in this biological fluid. Formulation of RC-101
into a film maintained the stability of RC-101 in HVF
for the same time period. However, it was found that
the presence of BV in HVF considerably affects the sta-
bility of RC-101. Given the favourable results from the
preformulation studies showing RC-101 to have a
favourable stability profile and potential for achieving
long term drug presence in the biological compartment
RC-101 has great potential to advance in development
as a microbicide drug candidate. Furthermore, the
results described in this study underscore the impor-
tance of assessing the impact of human vaginal fluid on
all potential microbicide products during the develop-
ment process.
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